Compare KLIC & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KLIC | CRNX |
|---|---|---|
| Founded | 1951 | 2008 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.9B |
| IPO Year | 2004 | 2018 |
| Metric | KLIC | CRNX |
|---|---|---|
| Price | $64.40 | $33.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $54.67 | ★ $74.78 |
| AVG Volume (30 Days) | 499.4K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | ★ 100.32 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $654,081,000.00 | $1,039,000.00 |
| Revenue This Year | $45.04 | $722.66 |
| Revenue Next Year | $11.95 | $183.79 |
| P/E Ratio | $202.31 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.63 | $24.10 |
| 52 Week High | $77.50 | $57.99 |
| Indicator | KLIC | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 47.07 | 29.20 |
| Support Level | $61.28 | $33.23 |
| Resistance Level | $72.90 | $37.23 |
| Average True Range (ATR) | 2.61 | 1.62 |
| MACD | -0.20 | 0.13 |
| Stochastic Oscillator | 31.30 | 8.33 |
Kulicke & Soffa Industries Inc. is a United States-based company that is principally engaged in designing, manufacturing, and selling capital equipment and expendable tools that are used for assembling semiconductor devices. The company has four reportable segments, which include Ball Bonding Equipment, Wedge Bonding Equipment, Advanced Solutions, and Aftermarket Products and Services. Its Ball Bonding Equipment segment which generates the majority of the revenue for the company includes results of the company from the design, development, manufacture and sale of ball bonding equipment and wafer level bonding equipment. The majority of its customers are located in the Asia-pacific region.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.